Scarica l'app Stockscreener
2.505
2.91%
-0.075
Dopo l'orario di chiusura:
2.64
0.135
+5.39%
Precedente Chiudi:
$2.58
Aprire:
$2.58
Volume 24 ore:
141.77K
Relative Volume:
0.34
Capitalizzazione di mercato:
$89.40M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-27.39%
1M Prestazione:
-26.11%
6M Prestazione:
-77.93%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.50
$2.625
Intervallo di 1 settimana:
$2.50
$3.56
Portata 52W:
$1.0779
$55.00
Fibrobiologics Inc Stock (FBLG) Company Profile
Nome
Fibrobiologics Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta FBLG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| FBLG | 2.505 | 89.40M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Fibrobiologics Inc Borsa (FBLG) Ultime notizie
HC Wainwright Expects Stronger Earnings for FibroBiologics - MarketBeat
Fibrobiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction in Cell-Based Therapeutics - Marketscreener.com
FibroBiologics files patent for reducing cell therapy risks - Investing.com
FibroBiologics seeks patent for clot-prevention method - Investing.com
FibroBiologics Files Patent Application Covering Reduction - GlobeNewswire
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with ... - The Bakersfield Californian
FibroBiologics Files Patent for Breakthrough Cell Therapy Blood Clotting Prevention | FBLG Stock News - StockTitan
Is FibroBiologics (NASDAQ:FBLG) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
FibroBiologics' (FBLG) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
FibroBiologics Reports Wider Q3 Loss, Advances Clinical Pipeline Amid R&D Push | FBLG Stock News - StockTitan
FibroBiologics Inc. (FBLG) Quarterly 10-Q Report - Quartzy
FBLGFibroBiologics, Inc. Latest Stock News & Market Updates - StockTitan
HC Wainwright Begins Coverage on FibroBiologics (NASDAQ:FBLG) - Defense World
HC Wainwright Forecasts FibroBiologics Q3 Earnings - MarketBeat
H.C. Wainwright sets stock target on FibroBiologics shares, cites portfolio By Investing.com - Investing.com Australia
FibroBiologics (NASDAQ:FBLG) Coverage Initiated by Analysts at HC Wainwright - MarketBeat
FibroBiologics names interim CFO as Mark Andersen steps down By Investing.com - Investing.com Australia
FibroBiologics CFO Andersen Resigns - MarketWatch
FibroBiologics names interim CFO as Mark Andersen steps down - Investing.com India
FibroBiologics reports breakthrough in artificial thymus research - Investing.com
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology - GlobeNewswire
FibroBiologics, Inc. Announces Updates for Novel Artificial Thymus Organoid Technology - Marketscreener.com
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024 - GlobeNewswire
FibroBiologics and Charles River link for chronic disease therapies manufacture - Yahoo News
FibroBiologics, Charles River Partner To Manufacture Cell-Based Therapies - Contract Pharma
FibroBiologics partners with Charles River for DFU trial production - Investing.com
FibroBiologics and Charles River Announce Collaboration to - GlobeNewswire
FibroBiologics partners with Charles River for DFU trial production By Investing.com - Investing.com UK
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based ... - Post Register
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases - ForexTV.com
FibroBiologics Shares Rise After European Patent for Fibroblast Cancer Treatment - MarketWatch
FibroBiologics secures patent for cancer treatment method - Investing.com
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office - GlobeNewswire
Short Interest in FibroBiologics, Inc. (NASDAQ:FBLG) Increases By 21.6% - MarketBeat
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit - The Manila Times
FBLG Stock Earnings: FibroBiologics, Inc. – Common Stock Reported Results for Q1 2024 - MSN
FibroBiologics, Inc. (NASDAQ:FBLG) Short Interest Update - MarketBeat
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa - GlobeNewswire
Take off with FibroBiologics Inc (FBLG): Get ready for trading - SETE News
FibroBiologics (NASDAQ:FBLG) Now Covered by Analysts at Maxim Group - MarketBeat
Maxim Group Initiates Coverage of FibroBiologics (FBLG) with Buy Recommendation - MSN
Market Insights: FibroBiologics Inc (FBLG)’s Notable Gain of 4.43, Closing at 3.30 - The Dwinnex
Falcon’s Beyond Global, Inc. (NASDAQ:FBYDW) Short Interest Update - Defense World
FibroBiologics engages Southern Star Research as CRO in Australia - TipRanks
FibroBiologics Engages Southern Star Research as CRO in Australia - GlobeNewswire
Five9, Inc. (NASDAQ:FIVN) Shares Acquired by Edgestream Partners L.P. - Defense World
FibroGen Inc (FGEN) can make a big difference with a little luck - SETE News
FibroGen Inc (FGEN) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Brown Brothers Harriman & Co. Has $104,000 Holdings in Fidus Investment Co. (NASDAQ:FDUS) - Defense World
Fibrobiologics Inc Azioni (FBLG) Dati Finanziari
Non sono disponibili dati finanziari per Fibrobiologics Inc (FBLG). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Fibrobiologics Inc Azioni (FBLG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Khoja Hamid | Chief Scientific Officer |
Aug 12 '24 |
Buy |
1.90 |
10,000 |
19,000 |
11,250 |
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):